Top movers in Wednesday's session Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.
These stocks are moving in today's session Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.
Traders are paying attention to the gapping stocks in Wednesday's session. In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down.
Edgewise Therapeutics Sees Meaningful HCM Treatment Gains With EDG-7500 In Phase 2 Study Edgewise's EDG-7500 lowered LVOT gradient and NT-proBNP levels in HCM patients, improving symptoms. Initial Part D data is expected in late 2025.
These stocks are moving in today's pre-market session The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Why Edgewise Therapeutics (EWTX) Stock Is Falling Edgewise Therapeutics shares are trading lower by 25.7% during Wednesday's session. The company announced an approximate $200 million offering.
Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged Edgewise Therapeutics stock dropped, as Cytokinetics shares got a big boost early Wednesday.
Dow Eyes Worst Losing Streak Since 2018 The Nasdaq Composite is up triple digits midday, hitting fresh record highs as it looks to build off a fourth-straight weekly win.
Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease Edgewise Therapeutics reports promising Phase 2 results for sevasemten, showing reduced muscle damage and well-tolerated safety in Becker muscular dystrophy.
Why Edgewise Therapeutics Stock Is Up 50% on Thursday One of the biopharma company's heart drugs performs as well as initially hoped.
Edgewise Therapeutics Stock Shoots Higher On Promising Early Results For Thickened Heart Treatment Edgewise Therapeutics announced topline data from Phase 1 and Phase 2 trials of EDG-7500 for obstructive hypertrophic cardiomyopathy, showing the drug was well tolerated with reductions in LVOT pressure gradient and NT-proBNP levels.
Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip Edgewise Therapeutics is trying to edge into a market already owned by Bristol Myers Squibb, just behind Cytokinetics.
EWTX Stock Earnings: Edgewise Therapeutics Beats EPS for Q2 2024 EWTX stock results show that Edgewise Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
7 Small-Cap Stocks to Buy for Large-Scale Gains Although small-cap stocks are incredibly risky, their underappreciated nature potentially gives them a high performance ceiling.
